Elizabeth H.Z. Thompson - Aug 12, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Head of Research & Dev
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Aug 12, 2024
Transactions value $
$0
Form type
4
Date filed
8/13/2024, 06:05 PM
Previous filing
Jul 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +325K $0.00 325K Aug 12, 2024 Common Stock 325K $15.29 Direct F1
transaction ACAD Restricted Stock Units Award $0 +64.5K $0.00 64.5K Aug 12, 2024 Common Stock 64.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on July 29, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3 50% of the restricted stock units vest on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.